Clal Biotechnology traded at 34.10 this Wednesday May 13th. Looking back, over the last four weeks, Clal Biotechnology lost 0 percent. Over the last 12 months, its price rose by 4.28 percent. Looking ahead, we forecast Clal Biotechnology to be priced at 33.10 by the end of this quarter and at 30.26 in one year, according to Trading Economics global macro models projections and analysts expectations.
Clal Biotechnology Industries Ltd (CBI) is an Israel-based biotechnology investment company. CBI's investments are targeted at bio-pharmaceutical companies, which are at different stages of research and development. The Company is a 59%-owned subsidiary of Clal Industries and Investments Ltd. (CII) that is part of IDB group. Clal Biotechnology Industries Ltd. has a number of portfolio companies, namely Andromeda Biotech Ltd., engaged in the field of type 1 diabetes; D-Pharm Ltd and Trombutech, engaged in the field of ischemic stroke; Mediwound Ltd., engaged in burn and wound management; Biokine Ltd, Biocancell Ltd and CureTech, engaged in the field of cancer; Braintact, engaged in the CNS field and Polyheal Ltd, engaged in wound management, among others.